AdventHealth Translational Research Institute
Trial Pipeline
Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis
NCT06993454
Assessments of Adipogenesis, Lipid Turnover and Cellular Composition in Adipose Tissue in Response to Endurance Exercise
NCT06602141
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
NCT06008977
Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D)
NCT06908057
ImpaCt Of Shiftwork on METabolic Flexibility and Skeletal Muscle Clocks
NCT05820490
Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer
NCT05773144
Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer
NCT05789433
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
NCT04807868
Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes
NCT04754581
Investigating the Effects of Aerobic and Resistance Training in Vivo on Skeletal Muscle Metabolism in Vitro in Primary Human Muscle Cells (MoTrMyo)
NCT04334343
The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults
NCT03761446
Magnetic Resonance & Optical Spectroscopy Validation
NCT01827527
Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications
NCT02663362
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
NCT06054529
Low-CArbohydrate Diet and SGLT2-INhibitOr to Achieve Moderate Ketosis in Healthy Volunteers
NCT05662865
Davos Alzheimer's Collaborative Study: Sequential Administration of Digital Testing To Screen For Cognitive Impairment Followed By Blood Based Biomarkers To Assist With Timely Detection And Accurate Diagnosis Of Alzheimer's Disease
NCT05379348
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
NCT05209100
REsearching Covid-19 Outcomes in Diabetes (RECODE)
NCT04805970
Effects of MetAP2 Inhibition on Bioenergetics and Aging-associated Characteristics in Adipose Tissue in Healthy Participants
NCT05989035
Transcriptional and Epigenetic Program of PCOS Women
NCT04034706
Development of Novel Biomarkers for the Early Diagnosis of Type 1 Diabetes
NCT04164966
CharacterIzation of Adult Onset Autoimmune Diabetes
NCT03971955
Electrical Stimulation of Human Myocytes in Microgravity
NCT03665051
Brown Adipose Tissue Pilot
NCT03793127
Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects
NCT03139305
Identifying Targets of Maladaptive Metabolic Responses in Heart Failure
NCT03032627
To Determine Tolerability to Glucagon Infusion in Obese Subjects
NCT02817659
Epigenetic Regulation of Human Adipose Tissue Distribution
NCT02728635
Collection of Human Tissue Samples From the Neck Region for Characterization of Its Molecular and Biochemical Signatures
NCT02274805
Muscle Insulin Resistance in Aging (Mirage)
NCT02230839
Exercise Resistance in Type 2 Diabetes
NCT01911104
Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)
NCT01911091
Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)
NCT01745471
Effects of Glucagon Administration on Energy Expenditure
NCT02237053
Intestinal Sweet Taste Receptor Function and Adaptation to Dietary Sugars and Sweeteners
NCT02835859
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
Therapeutic Areas
What the Pipeline for AdventHealth Translational Research Institute Shows
According to the ClinicalTrials.gov registry, AdventHealth Translational Research Institute is linked to 35 US clinical trials across every stage of research activity. Of those, 13 studies are currently recruiting — about 37% of the sponsor's indexed portfolio — and 2 are already marked complete, representing roughly 6% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for AdventHealth Translational Research Institute reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 4 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for AdventHealth Translational Research Institute is Obesity with 7 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.